4 min 
About the Customer
Integrated Health Partners of Southern California (IHP) is a clinically integrated network serving 330,000 attributed lives, including approximately 320,000 Medi-Cal beneficiaries.
Problem
Need to understand barriers to treatment resulting in rising costs
Outcome
43% reduction in infusion-related spending
Turning integrated data into action for value-based care performance
Specialty infusion therapies represented a growing source of healthcare spending for IHP, a clinically integrated network serving 330,000 attributed lives, including approximately 320,000 Medi-Cal beneficiaries. The organization needed to better understand what caused barriers to treatment resulting in rising costs, then identify opportunities to improve both patient access and financial performance.
Using Arcadia’s healthcare performance platform, IHP integrated clinical, claims, utilization, quality, and social determinants data into a unified view. This enabled IHP to identify high-cost utilization, uncover barriers to treatment, measure site-of-care interventions, and support future optimization.
Integrated Health Partners of Southern California
9
Member Federally Qualified Health Centers
110
Sites Managed
350,000+
Medi-Cal Patients Managed
Discovering hidden barriers through integrated analytics
Traditional reporting limited IHP’s visibility into the causes of treatment disruptions and high costs.
Working with Arcadia to conduct a deeper analysis, IHP discovered a small cohort of 12 patients with multiple sclerosis who represented more than $1 million in annual utilization costs due to inconsistent adherence to infusion therapies, frequent emergency department visits, and hospitalizations. Further investigation revealed transportation and geographic barriers preventing many patients from consistently accessing treatment.
Rather than focusing solely on cost reduction, IHP sought to address the underlying barriers preventing patients from receiving consistent treatment by establishing three objectives:
- Improve access for patients facing transportation and geographic barriers
- Reduce avoidable and expensive infusion-related costs
- Create a scalable framework for effectively managing high-cost services
Delivering measurable financial and operational results
Using Arcadia’s analytics and workflow capabilities, IHP collaborated with primary care clinicians, subspecialists, health plans, hospital partners, home health agencies, and care management teams to transition clinically appropriate patients from hospital-based infusion care to more convenient settings.
In a pilot program, patients were offered infusion services closer to home, including community and outpatient settings and, when appropriate, home-based infusion, to improve access while maintaining quality and patient choice.
Through these efforts, IHP demonstrated that it could simultaneously maintain quality performance, reduce unnecessary costs, and improve patient outcomes. For patients, receiving care closer to home strengthened access to treatment, improved convenience, and reduced travel burdens.
Receiving my infusions at home has made a big difference in my care. I no longer worry about the exhausting and costly trips to the hospital. It’s made a huge difference in my quality of life.
IHP patient receiving home-based infusion therapy
Scaling from a pilot program to an enterprise strategy
The pilot became a scalable business intelligence and operational framework for identifying, implementing, monitoring, and scaling site-of-care optimization initiatives across infusion-dependent conditions, including ulcerative colitis and rheumatoid arthritis.
Between 2023 and 2025, infusion-related expenditures decreased by 43% from approximately $1.4 million to $801,489. While multiple factors likely contributed to this trend, organizational analyses identified site-of-care optimization as an important contributor to the observed reduction.
IHP also estimated approximately $1 million in measurable savings associated with transitioning clinically appropriate patients from higher-cost facility-based settings to lower-cost home- and community-based infusion. These savings reflected avoided facility charges, reduced administrative fees, and lower medication-related costs associated with delivering infusion therapy in more appropriate care settings.
At the same time, the adoption of home infusion accelerated significantly. The number of patients receiving home-based infusions increased from six in 2024 to 42 in 2025, a 600% increase that demonstrated both patient acceptance and operational scalability.
The initiative also contributed to broader population health improvements. IHP observed a 2.2% reduction in emergency department utilization across its value-based care population over a 12-month period.
Looking ahead
IHP’s experience demonstrates that integrated data can do more than identify high-cost utilization. When combined with effective workflows and stakeholder alignment, it can reveal hidden barriers to care, improve patient access, and create scalable opportunities for better health and financial sustainability.
“Too often, organizations focus on the cost of care without fully understanding the barriers patients face in accessing it. By bringing together clinical, claims, and utilization data, we were able to see that transportation and geography were contributing to treatment disruptions and avoidable utilization. Addressing those barriers helped us improve access for our patients while creating a scalable model for managing high-cost services across our network.”
Customer Outcomes
estimated site-of-care savings
reduction in infusion-related spending over three years
increase in home infusion utilization
